扩张型心肌病患者血清sICAM-1水平及其临床意义研究

Research of clinical of serum soluble ICAM-1 in dilated cardiomyopathy

目的探讨扩张型心肌病患者血清可溶性胞间黏附因子-1(sICAM-1)水平与扩张型心肌病的发生发展的关系及临床意义。方法应用酶联免疫双抗体夹心法(ELISA)测定25例扩张型心肌病患者和15例健康对照组的血清sICAM-1水平。所有扩张型心肌病患者均经过超声心动图、X线胸片、心电图等多项检查证实,确属不明原因的心脏扩大伴有不同程度的心肌收缩功能减退,左室射血分数(LVEF)<35%者。结果扩张型心肌病组血清sICAM-1明显高于对照组[(162.46±78.56)ng/ml,69.48ng/ml,P<0.01];心功能Ⅱ级组血清sICAM-1高于对照组[(99.80±13.49)ng/ml,(69.48±16.86)ng/ml,P<0.05];心功能Ⅲ级组血清sICAM-1水平明显均高于心功能Ⅱ级组[(188.40±27.15)ng/ml,(99.80±13.49)ng/ml,P<0.01],心功能Ⅳ级组血清sICAM-1水平明显高于心功能Ⅲ级组[(370.85±49.97)ng/ml,(188.40±27.15)ng/ml,P<0.01]。结论扩张型心肌病患者血清中sICAM-1高表达,并且随着心衰加重,外周血清中sICAM-1的水平逐渐升高。在DCM中。

Objective To detect serum levels of soluble intercellular adhesion molecule-1, and to evaluate the significance of it in dilated cardiomyopathy. Methods By enzyme-linked immunosorbent assay （ELISA）, serum levels of sICAM-1 was measured in the sera from 25 patients with DCM and 15 control groups. All dilated cardiomyopathy patients were confirmed by UCG, chest X-ray film, ECG and so on. To remove other specificity myocardiopathy and endemic cardiomyopathy, they were sure in nubibus reason cardiac dilatation with different muscle contraction hypofunction,lefe ventricle ejection fraction（EF〈35%）. Results Significant increase in the concentrations of sICAM -1 was found in the serum from patients with DCM relative to controls [ （162.46±78.56）ng/ml, 69.48 ng/ml,P〈0.01]. Mean level of sICAM -1 was significantly higher in patients with heart function Ⅱ than those in control group [ （99.80±13.49）ng/ml, （69.48±16.86）ng/ml,P〈0.05 ]. The level of sICAM -1 was significandy higher in patients with heart function m than those in heart function Ⅱ [（188.40±27.15）ng/ml, （99.80± 13.49）ng/ml,P〈0.01]. The level of sICAM -1 was significantly higher in patients with heart function Ⅳgroup than those in heart functionm [（370.85±49.97）ng/ml,（188.40±27.15）ng/ml,P〈0.01].Conclusion Serum levels of soluble intercellular adhesion molecule-1 was very high in patients with dilated cardiomyopathy, moreover, it was more and more higher with cardia insufficiency to aggravate. ICAM-1 should be regarded as a kind of tumor marker without being injuryed in patients with dilated cardiomyopathy.